Melissa A. Burgess

Melissa A. Burgess

Hematology Oncology

5115 Centre Avenue, Hillman Cancer Center
Pittsburgh, PA 15232

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 18, 2026

ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival.

ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival.

Journal: ESMO rare cancers

Published: April 17, 2026

ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival.

ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival.

Journal: medRxiv : the preprint server for health sciences

Published: December 03, 2025

Expanding the Spectrum of SRF-Rearranged Myoid Tumors: An Adult Case With SRF::SOHLH1 Fusion and Suspected Metastasis.

Expanding the Spectrum of SRF-Rearranged Myoid Tumors: An Adult Case With SRF::SOHLH1 Fusion and Suspected Metastasis.

Journal: Genes, chromosomes & cancer

Published: August 11, 2025

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

Journal: medRxiv : the preprint server for health sciences

Published: August 08, 2025

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

Journal: The oncologist

Published: July 19, 2025

Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.

Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 18, 2025

Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).

Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).

Journal: Journal for immunotherapy of cancer

Published: July 11, 2025

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer

Published: July 04, 2025

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Journal: Nature medicine

Published: June 27, 2025

Malignant ossifying fibromyxoid tumour with TP53::PHF1 fusion: report of three cases suggesting an association between rare fusions and malignant phenotypes.

Malignant ossifying fibromyxoid tumour with TP53::PHF1 fusion: report of three cases suggesting an association between rare fusions and malignant phenotypes.

Journal: Histopathology

Published: May 22, 2025

SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance.

SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 21, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026